MedTrace Logo

Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)

NCT00880243 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 473

Last updated 2009-04-13

No results posted yet for this study

Summary

The purpose of this study is:

1. To compare priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) during induction and consolidation courses versus no priming.
2. To compare as consolidation timed sequential chemotherapy versus four courses of high dose cytarabine.

Conditions

Interventions

DRUG

GM-CSF

Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses. Randomiization 2: Consolidation high dose AraC versus consolidation EMA

Sponsors & Collaborators

  • Hospices Civils de Lyon

    collaborator OTHER

  • Acute Leukemia French Association

    lead OTHER

Principal Investigators

  • XAVIER THOMAS, MD, PhD · Hospices Civils de Lyon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-03-31
Primary Completion
2006-09-30
Completion
2006-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00880243 on ClinicalTrials.gov